Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Accelyon
Cambridge, Massachusetts, United Statesbxta.com ↗
- Ownership
- Private
- Employees
- ~312
- Development stage
- Other
01
Overview
Acceleron's lead programs include REBLOZYL (luspatercept-aamt), a first-in-class erythroid maturation agent approved in the US, Europe, Canada, and Australia for anemia in rare blood disorders[5], and sotatercept, which completed Phase 3 trials for pulmonary arterial hypertension[1][5].
- Therapeutic areas
- HematologyCardiovascularNeurologyOncology
- Modalities
- Recombinant fusion protein
- Industry
- Biotech
02
Partnerships
Bristol Myers Squibb (global collaboration for luspatercept development and commercialization)Celgene (partnership for ACE-011 and ACE-536 development, 2008-2011)
Beyond the preview
Go deeper on Accelyon.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Accelyon.